Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-27T23:14:24.535Z Has data issue: false hasContentIssue false
  • English
  • Français

TOPAMAX

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 2 , May 1997 , pp. xxxvii - xxxix
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

REFERENCES:

1.Faught, E.et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684–90.CrossRefGoogle ScholarPubMed
2.TOPAMAX (topiramatel Product Monograph. Janssen-Ortho Inc., 1997.Google Scholar
3.Walker, MC and Sander, JWAS. Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure 1996; 5: 199–203.CrossRefGoogle ScholarPubMed
4.Shorvan, SDSafety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 (suppl)2): s18–22.Google Scholar